VEGFA and neoplasm: Notably, lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1–3, platelet-derived growth factor (PDGF) receptor alpha, fibroblast growth factor (FGF) receptors 1–4, rearranged during transfection (RET), and KIT, which draws a strong anti-tumor response in HCC cases [14,15,16,17].